Noticias y vídeos - NEXTCURE INC.

Prioritize and focus resources on LNCB74 (B7-H4 ADC) with a planned IND submission by year-end Cash of approximately $75 million expected to fund operations into second half of 2026 BELTSVILLE, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported third-quarter 2024 financial results....

Preclinical data for LNCB74 highlights its potential as therapeutic for treating multiple solid tumor indications; Investigational New Drug (IND) application filing expected by year-end Additional biomarker data support proposed mechanism of action of NC410 BELTSVILLE, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today...

BELTSVILLE, Md., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced two presentations at the Society for Immunotherapy of Cancer (SITC) annual meeting, to be held in Houston, TX from November 6-10, 2024. NextCure will share pre-clinical data from LNCB74 (B7-H4 ADC) and biomarker data from NC410 combination study with...

Of the 20 evaluable ovarian cancer patients, there were 5 PRs Of the 43 evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 3 PRs Biomarker data support proposed mechanism of action of NC410 BELTSVILLE, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical data from the...

LNCB74 (B7-H4 ADC) GLP tox studies completed and targeting an IND application by year-end NC410 combo with pembrolizumab ovarian cohort enrollment completed Cash of approximately $86.4 million expected to fund operations into second half of 2026 BELTSVILLE, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- – NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a...

BELTSVILLE, Md., June 20, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies, today announced that it will present and host institutional investor meetings at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on Thursday, June 27, 2024. A recording of the webcast will be available on the conference day starting at 7 AM ET through the...

Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51% Of the 7 evaluable ovarian cancer patients, there were 3 PRs and a disease control rate of 43% Data to be presented June 1, 2024, 9:00 am-12:00 pm CT BELTSVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class...

Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1 Presented preclinical data from LNCB74 (B7-H4 ADC) at recent AACR annual meeting Cash of approximately $96.0 million expected to fund operations into second half of 2026 BELTSVILLE, Md., May 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today...

BELTSVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical trial investigator Eric S. Christenson, M.D., Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, will present a poster on clinical data from the Phase 1b portion of a study evaluating NC410 in...

BELTSVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the presentation of new preclinical data on LNCB74, a B7-H4-targeting antibody drug conjugate (ADC) developed in partnership with LigaChem Biosciences (LCB), formerly LegoChem Biosciences, (KOSDAQ: 141080), at the 2024 American Association for Cancer...

BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board. As an accomplished product developer whose expertise is focused on antibody-drug conjugates (ADCs), Dr. Dixit will support NextCure in its efforts to build and develop its...

BELTSVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will present at the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11 th , at 12:45 pm ET. A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com . A replay of...

Prioritizing and focusing on highest-value opportunities NC410 (ovarian and CRC) and LNCB74 (B7-H4 ADC) Based on early evidence of clinical activity with NC410 combo, expanding ovarian and CRC cohorts with data updates in 2024 LNCB74, in collaboration with LegoChem, planned filing of an IND by year-end 2024 Restructuring of our operations, including a reduction in workforce to better align resources toward prioritized programs Cash of approximately $108 million, combined with the restructuring,...

BELTSVILLE, Md., March 05, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a manuscript titled “The FLRT3-UNC5B Checkpoint Pathway Inhibits T Cell-Based Cancer Immunotherapies” in the journal Science Advances , published by the American Association for the Advancement of Science....

BELTSVILLE, Md., Jan. 18, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentation of preclinical data relating to a novel humanized monoclonal antibody targeting VSTM-1, for the treatment of progressive inflammatory airway disorders, including chronic obstructive pulmonary disease (COPD), at...

BELTSVILLE, Md., Dec. 21, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a manuscript titled “ Anti-Siglec-15 Antibody Prevents Marked Bone Loss after Acute Spinal Cord Injury-Induced Immobilization in Rats ” in JMBR Plus , a journal of the American Society for Bone and Mineral...

BELTSVILLE, Md., Dec. 14, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on its clinical pipeline. NC410 (LAIR-2 fusion) The Phase 1b combination trial of NC410 with pembrolizumab is ongoing. Given evidence of clinical activity to date, additional patients are being added to the 100 mg cohort...

BELTSVILLE, Md., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the 35th Annual Piper Sandler Healthcare Conference in New York City on Thursday, November 30 th , at 1:30 pm ET. A live audio webcast will be available through the Investors section...

New publication in Journal of Clinical Investigation provides compelling evidence for NC525’s ability to specifically kill leukemic cells while sparing healthy cells in non-clinical modeling Update for ongoing Phase 1a clinical trial is expected in the fourth quarter of 2023 BELTSVILLE, Md., Nov. 15, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and...

Phase 1b updates for NC410 and NC762, and operational update for NC525 Phase 1a are expected by year end Cash of approximately $118 million expected to fund operations into mid-2025 BELTSVILLE, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases today provided a business update and reported third quarter 2023...